Is NCT03125642 recruiting in Minneapolis, MN?

Yes, NCT03125642 is currently recruiting participants at its Minneapolis, MN location. This non-hodgkin lymphoma clinical trial is actively enrolling qualified participants.

How do I join the non-hodgkin lymphoma clinical trial in Minneapolis?

To join this clinical trial in Minneapolis, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Minneapolis clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Non-Hodgkin Lymphoma Clinical Trial in Minneapolis, MN

Who Can Participate

Inclusion Criteria

Eligible Diseases

Non-Hodgkin's Lymphoma (NHL)

Patients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification.

Patients in partial or complete remission following cell therapy will also be eligible.

NHL patients with resistant or refractory lymphoma (no PR following up to three cycles of combination chemotherapy) will not be eligible for transplant in this trial.

Lymphoblastic Lymphoma:

All patients will be eligible in second or greater complete remission (CR) or first or subsequent partial remission (PR)

Patients with any high-risk features will be eligible in first complete remission

High risk features include: Stage IV, LDH \>2 x upper limit of normal, ≥ 2 extranodal sites

Mature B-cell Lymphoma

Follicular Lymphoma and other indolent lymphoma in ≥ second CR2/PR2

Diffuse Large B-Cell Lymphoma: in ≥ CR2 or ≥ PR1; a high intermediate or high IPI (≥ 2 for age-adjusted IPI or ≥3 for IPI) at diagnosis and double-hit or triple-hit lymphoma will be eligible in first CR; transformed lymphoma from FL (or other indolent lymphoma) or chronic lymphocytic leukemia will be eligible if chemosensitive and bone marrow is negative

Mantle Cell Lymphoma: in first or greater CR or PR

Burkitt's/Burkitt's like: all patients except localized lymphoma will be eligible any time after initial therapy (after achievement of first complete remission), or in partial remission if they fail to achieve CR; patients with localized (stage I or Ziegler stage A) will be eligible only if they fail to achieve CR1 or after relapse

Mature T-Cell Lymphoma

Chemosensitive T-cell lymphomas including Primary T-cell not otherwise specified angioimmunoblastic, and ALK-positive anaplastic large cell, will be eligible after initial therapy, whether or not CR is achieved.

Mycosis fungoides/Sezary syndrome will be eligible in ≥CR2/PR2

Hodgkin Lymphoma (HL)

Patients with histologically proven HL will be eligible for transplantation after failing prior therapy.

Patients with resistant disease (initial or at relapse): those who fail to achieve an objective partial response to three cycles of combination non-cross resistant chemotherapy will not be eligible for transplant in this trial.

For stage I/II patients treated with primary chemotherapy-radiation, they must have failed (no CR or progression after CR) at least one salvage combination chemotherapy treatment regimen

For advanced (stage III/IV) Hodgkin disease, patients must have failed an Adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g. MOPP)

Patients with any high-risk features will also be eligible, including those who:

fail to achieve complete remission with initial combination chemotherapy

have bulky disease after initial therapy (chemotherapy or radiation) defined as residual mediastinal mass ≥ 5 cm or other residual mass ≥ 10 cm accompanied by other features of persisting disease (e.g., PET scan positive; high LDH; enlarging on serial x-rays or biopsy positive) will be eligible - if feasible, persistent disease should be proven by biopsy

Patients should receive chemotherapy to attempt to achieve CR or minimal disease state for all patients pre-transplantation. The use of up to three cycles of non-cross resistant combination chemotherapy is advised.

Residual areas of limited disease should be considered for radiotherapy after and not prior to transplantation.

HIV positive patients who are otherwise eligible for this study may be enrolled if they meet the following requirements:

Are seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period.

Are on maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians. For the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor.

CD4+ ≥ 50/µL

HIV RNA viral load ≤ 100,000 copies per mL on each of samples 4 weeks apart. The most recent level must be within 30 days of enrollment.

Performance Status: Karnofsky Performance Status ≥ 80% for patients ≥ 16 years of age or Lansky Play Score ≥ 80 for patients \< 16 years of age. Note: if poor performance status is due to lymphoma - KPS ≥ 60% or LPS ≥ 60 is acceptable

Organ Function 1\. No evidence of serious organ dysfunction that is not attributable to tumor including:

Hematologic:

hemoglobin \> 8 gm/dL

WBC \> 2.5 x 109/L with an ANC \> 1.5 x 109/L off G-CSF or GM-CSF for 10 days or Neulasta for 21 days

platelets \> 100 x 109/L without transfusion

bone marrow cellularity of \> 20% with \<5% involvement with tumor

Renal: GFR \> 50 ml/min/1.73m2 or serum creatinine ≤ 2.5 x ULN for age

Hepatic: no history of severe prior or ongoing chronic liver disease. Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase \<5x upper limit of normal

Cardiac: free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia. The ejection fraction by gated cardiac blood flow scan (MUGA) or Echocardiogram must be \>40%

Pulmonary: no significant obstructive airways disease (FEV1 must be ≥ 50%) and must have acceptable diffusion capacity (corrected DLCO \> 50% of predicted)

Central Nervous System: Patients with a history of CNS involvement by lymphoma or with relapsed primary CNS lymphoma will be eligible for Cy/TBI arm. Patients with active CNS disease are eligible if they have completed a standard treatment for CNS lymphoma and have no evidence of progressive CNS disease at the time of enrollment

Other Inclusion Criteria

At least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas

Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment

Patients who are carriers of Hepatitis B will be included in this study

Voluntary written consent

Exclusion Criteria

Pregnant or breastfeeding: Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy

Eligible for any higher priority transplant protocols

Chemotherapy resistant disease

Unrelated active infection

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT03125642) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Hodgkin Lymphoma Treatment Options in Minneapolis, MN

If you're searching for non-hodgkin lymphoma treatment options in Minneapolis, MN, this clinical trial (NCT03125642) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced non-hodgkin lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-hodgkin lymphoma clinical trials near you to find additional studies recruiting in your area.

Non-Hodgkin Lymphoma Clinical Trial in Minneapolis, MN

Expert Care in Minneapolis

IRB Approved

No-Cost Care

Apply for This Minneapolis Location

Why Participate?

Simple Process

About This Non-Hodgkin Lymphoma Study in Minneapolis